Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct 19;372(1732):20160274.
doi: 10.1098/rstb.2016.0274.

Viral hepatitis and liver cancer

Marc Ringelhan  1   2   3 , Jane A McKeating  4   5 , Ulrike Protzer  6   3   7
Affiliations
Review

Viral hepatitis and liver cancer

Marc Ringelhan et al. Philos Trans R Soc Lond B Biol Sci. .

Erratum in

  • Correction to 'Viral hepatitis and liver cancer'.
    Ringelhan M, McKeating JA, Protzer U. Ringelhan M, et al. Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):20170339. doi: 10.1098/rstb.2017.0339. Philos Trans R Soc Lond B Biol Sci. 2018. PMID: 29158320 Free PMC article. No abstract available.

Abstract

Hepatitis B and C viruses are a global health problem causing acute and chronic infections that can lead to liver cirrhosis and hepatocellular carcinoma (HCC). These infections are the leading cause for HCC worldwide and are associated with significant mortality, accounting for more than 1.3 million deaths per year. Owing to its high incidence and resistance to treatment, liver cancer is the second leading cause of cancer-related death worldwide, with HCC representing approximately 90% of all primary liver cancer cases. The majority of viral-associated HCC cases develop in subjects with liver cirrhosis; however, hepatitis B virus infection can promote HCC development without prior end-stage liver disease. Thus, understanding the role of hepatitis B and C viral infections in HCC development is essential for the future design of treatments and therapies for this cancer. In this review, we summarize the current knowledge on hepatitis B and C virus hepatocarcinogenesis and highlight direct and indirect risk factors.This article is part of the themed issue 'Human oncogenic viruses'.

Keywords: chronic viral hepatitis; hepatitis B; hepatitis C; hepatocarcinogenesis; hepatocellular carcinoma; virus-induced cancer.

PubMed Disclaimer

Conflict of interest statement

We have no competing interests.

References

    1. Trepo C, Chan HL, Lok A. 2014. Hepatitis B virus infection. Lancet 384, 2053–2063. (10.1016/S0140-6736(14)60220-8) - DOI - PubMed
    1. Fattovich G, Bortolotti F, Donato F. 2008. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 48, 335–352. (10.1016/j.jhep.2007.11.011) - DOI - PubMed
    1. Guidotti LG, et al. 2015. Immunosurveillance of the liver by intravascular effector CD8+ T cells. Cell 161, 486–500. (10.1016/j.cell.2015.03.005) - DOI - PMC - PubMed
    1. Pan CQ, et al. 2016. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N. Engl. J. Med. 374, 2324–2334. (10.1056/NEJMoa1508660) - DOI - PubMed
    1. del Canho R, et al. 1997. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982–1992: protective efficacy and long-term immunogenicity. Vaccine 15, 1624–1630. (10.1016/S0264-410X(97)00080-7) - DOI - PubMed